Bispecific Stealth Lipid Nanoparticles for Precise Immune Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR T-cell therapies for cancer treatment face significant challenges, including life-threatening adverse reactions such as cytokine release syndrome, and there is a need for improved methods to efficiently and safely deliver therapeutic cargo to immune effector cells like T-cells, B-cells, NK cells, and hematopoietic stem cells in vivo, in vitro, or ex vivo.
Innovation Solution
Development of stealth lipid nanoparticles (LNPs) with enhanced blood circulation time and targeting capacity, incorporating specific targeting moieties like scFv and VHH, which provide prolonged half-life and efficient delivery of nucleic acids to desired cells, minimizing interactions with opsonins and ensuring robust linkage through DBCO or maleimide conjugation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional LNPs are used for delivering therapeutic cargo to immune effector cells, then delivery can be achieved, but blood circulation time is short and targeting specificity is insufficient
Solution Approach 1:
The patent applies local quality by incorporating specific lipid compositions and surface modifications at different regions of the LNP structure. The ionizable lipid and sterol components are positioned to provide stability and prolonged circulation, while targeting moieties are localized on the surface to ensure specific binding to immune effector cells without affecting overall particle stability.
Solution Approach 2:
The patent employs composite materials by combining multiple lipid types (ionizable lipid, sterol, lipid-anchored polymer) with targeting moieties (scFv, VHH) to create a multifunctional LNP system. This composite structure integrates prolonged circulation properties from the lipid composition with enhanced targeting specificity from the antibody fragments, resolving the contradiction between circulation time and targeting accuracy.
2Duration of action of moving object
If LNP surface is modified to increase circulation time, then blood half-life is prolonged, but interaction with opsonins increases
Solution Approach 1:
The patent applies parameter changes by carefully optimizing the lipid composition ratios and molecular weights of lipid-anchored polymers to achieve the right balance between circulation time and opsonin resistance. By adjusting these parameters, the LNP maintains prolonged blood half-life while minimizing harmful interactions with the immune system's opsonins.
3Productivity
If targeting moieties are conjugated to LNP, then cell targeting efficiency increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-conjugating targeting moieties (scFv, VHH) to lipid-anchored polymers before LNP assembly. This preliminary preparation of conjugated components simplifies the overall manufacturing process, as the targeting functionality is already integrated into the building blocks, reducing the complexity of final LNP production while maintaining high cell targeting efficiency.
Data Source
AI summary
The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.